CBD Outcome Guide
CBD and Seizures: What Makes the Evidence Different?
A source-led guide to CBD seizure research, regulated-product context, and why this evidence should not be transferred to every CBD product.
The short answer
What should you know first?
CBD seizure evidence includes closely studied, highly purified prescription formulations and specific seizure populations. That record is important, but it does not automatically describe other CBD products or conditions.
Key differences
Compare the right things
Key distinction
Product
Prescription-CBD research is not a result for every formulation.
Key distinction
Population
Specific seizure populations should not be collapsed into one broad claim.
Key distinction
Safety
Dose, monitoring, and co-medications are part of the study context.
What studies reported
Results worth understanding
These findings belong to the named compound or product, dose, route, population, and outcome. They are not one result for every cannabinoid product or person. Open the PubMed links to inspect the original records.
Randomized human trial
Dravet convulsive seizures decreased
In 120 children and young adults, 20 mg/kg/day of add-on oral CBD reduced monthly convulsive-seizure frequency more than placebo over 14 weeks. Nonconvulsive-seizure frequency did not significantly differ, and adverse events were more frequent with CBD. PubMed 28538134
Randomized human trial
Lennox-Gastaut drop seizures decreased
Among 225 patients, median drop-seizure frequency fell 41.9% with 20 mg/kg/day and 37.2% with 10 mg/kg/day, compared with 17.2% on placebo. The trial studied add-on prescription-formulation CBD in a defined syndrome. PubMed 29768152
Randomized human trial
Tuberous-sclerosis-complex seizures decreased
In 224 patients, seizure frequency fell more with 25 or 50 mg/kg/day CBD than placebo. The lower dose had a better safety profile; diarrhea, somnolence, discontinuations, and liver-enzyme elevations were important parts of the result. PubMed 33346789
Systematic review
Six randomized trials showed a replicated pattern
A review of six randomized trials across Dravet, Lennox-Gastaut, and tuberous sclerosis complex found fewer seizures and more responders with CBD, alongside increased adverse events, serious adverse events, discontinuation, and transaminase elevation. PubMed 36417631
Research context
Read the evidence in context
Seizures are the strongest established CBD outcome in this library
Multiple randomized placebo-controlled trials found that highly purified oral CBD, added to existing antiseizure treatment, reduced specific seizure frequencies in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. This is a materially stronger evidence pattern than the early, mixed records for many other CBD outcomes.
The evidence belongs to defined syndromes and seizure endpoints
Dravet convulsive seizures, Lennox-Gastaut drop seizures, and tuberous-sclerosis-complex-associated seizures are not one generic seizure outcome. Trials enrolled people meeting specific diagnostic and baseline-frequency criteria, then measured a defined seizure type over a defined treatment period. The strongest conclusion stays inside those boundaries.
Prescription formulation and add-on treatment are central facts
The pivotal trials used a highly purified oral CBD solution at weight-based doses while participants continued antiseizure medicines. That does not make every CBD oil equivalent, and it does not show that CBD should replace existing treatment. Product consistency, titration, co-medications, and monitoring were built into the clinical context.
Benefit came with measurable safety and interaction questions
Trials also reported diarrhea, somnolence, decreased appetite, treatment discontinuations, and liver-enzyme elevations in some settings. Co-medications such as clobazam or valproate can matter to the safety and interaction record. The seizure evidence is real, and so is the need to read it as monitored prescription research rather than a retail-product instruction.
Important limits
What can make the answer change?
- 1
Do not use this page as seizure-treatment guidance.
- 2
Do not transfer prescription-product findings to other products.
- 3
Do not separate seizure evidence from safety and medication context.
Common questions
Questions people ask
Does CBD reduce seizures?
Highly purified prescription CBD reduced specific seizure frequencies in randomized trials of Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex when added to existing antiseizure treatment. PubMed 28538134 PubMed 29768152 PubMed 33346789
Is this evidence about store-bought CBD?
No. The strongest trials used a standardized, highly purified oral prescription formulation with weight-based dosing and clinical monitoring. PubMed 28538134 PubMed 29768152
Did CBD stop seizures completely?
The major trials primarily showed reductions in defined seizure frequencies. They do not show that every patient became seizure-free, and some endpoints did not significantly improve. PubMed 28538134
What safety issues appeared in seizure trials?
Reported issues included diarrhea, somnolence, decreased appetite, discontinuation, medication interactions, and liver-enzyme elevations in some settings. PubMed 33346789 PubMed 36417631